CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
早期乳腺癌中的 TIL（肿瘤浸润淋巴细胞）：一项针对葡萄牙患者 HER2+亚型的探索性分析
英文原题：Tumor-infiltrating lymphocytes in early breast cancer: an exploratory analysis focused on HER2+ subtype in Portuguese patients.
查看英文原题
Tumor-infiltrating lymphocytes in early breast cancer: an exploratory analysis focused on HER2+ subtype in Portuguese patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
TIL（肿瘤浸润淋巴细胞）（TILs）在乳腺癌中已显示出预后价值。本研究评估了186例诊断为早期乳腺癌的葡萄牙患者的TILs评分，特别关注HER2亚型。在核心针穿刺活检标本上对间质TILs进行评分，同时对接受曲妥珠单抗和帕妥珠单抗新辅助治疗的HER2+患者的手术切除标本也进行了评分。在激素受体状态阴性、HER2扩增的肿瘤以及三阴性乳腺癌中，TILs较高。在接受双重抗HER新辅助治疗的HER2+患者中，手术标本上的TILs评分通常低于活检标本。
展开英文摘要原文
Tumor-infiltrating lymphocytes (TILs) have shown prognostic value in breast cancer.
This study evaluated the TILs scores in 186 Portuguese patients diagnosed with early breast cancer, with special focus on HER2 subtype. Stromal TILs were scored on the core needle biopsies, as well as in the resected specimen in HER2+ patients submitted to neoadjuvant treatment with trastuzumab and pertuzumab.
TILs were higher in tumors with negative hormone receptor status and HER2 amplifications, and in triple-negative breast cancer. In HER2+ patients treated with dual anti-HER neoadjuvant therapy, the TILs score on the surgical specimen was generally lower than in the biopsy.
论文信息
- 作者
- Luz P、Fernandes I、Magalhães J、Sousa RT、Faísca P、Costa JG、Fernandes AS
- 第一作者单位
- Department of Medical Oncology, Centro Hospitalar Universitário do Algarve, Rua Leão Penedo, Faro, Portugal.Portugal
- 通讯作者单位
- CBIOS - Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisboa, Portugal.Portugal
- 文献类型
- 非美国政府资助研究
- 期刊
- Current medical research and opinion2022 Aug
- 原文标识
- PubMed 35770865 · DOI 10.1080/03007995.2022.2096334